CN101972400A - Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion - Google Patents
Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion Download PDFInfo
- Publication number
- CN101972400A CN101972400A CN2010102990563A CN201010299056A CN101972400A CN 101972400 A CN101972400 A CN 101972400A CN 2010102990563 A CN2010102990563 A CN 2010102990563A CN 201010299056 A CN201010299056 A CN 201010299056A CN 101972400 A CN101972400 A CN 101972400A
- Authority
- CN
- China
- Prior art keywords
- hyposecretion
- hormore
- sealwort
- rhizoma polygonati
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of sealwort extract to preparing a medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion, which can effectively solve the medication problem of the women climacteric metancholia caused by in vivo female hormore hyposecretion. The technical scheme comprises the steps of: decocting sealwort twice with 10 times of water in the weight of the sealwort every time, wherein each time is 2h; merging two-times of water solutions, decompressing and concentrating as well as drying to obtain a sealwort extract which is used for effectively preparing the medicament for treating the women climacteric metancholia caused by the in vivo female hormore hyposecretion. The preparation method of the extract is simple, stable and reliable, obtains same or similar results through more than multiple experiments, is convenient, and is low in cost; and the extract is effectively used for preparing a female hormore medicament, develops the novel medication application of the sealwort, and has huge clinical meaning.
Description
One, technical field
The present invention relates to medicine, the application in particularly a kind of Rhizoma Polygonati water extract climacteric syndrome medicine that the estrogen hyposecretion causes in preparation is treated owing to body.
Two, background technology
Rhizoma Polygonati is for being the dry rhizome of liliaceous plant Yunnan Rhizoma Polygonati (Polygonatum kingianum Coll.et Hemsl.), Rhizoma Polygonati (Polygonatum sibiricum Red.) or Polygonatum cyrtonema Hua (Polygonatum cyrtonema Hua.).The successive dynasties famous expert all has argumentation and research to it, thinks that its property is sweet, flat, returns spleen, lung, kidney channel, has boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney benefiting functions.Be used for the treatment of weakness of the spleen and stomach, fatigue and asthenia, xerostomia lack of appetite, deficiency of the lung cough caused by dryness, asthenia of essence and blood, interior-heat disease such as quench one's thirst.Modern pharmacology and clinical research show that Rhizoma Polygonati has resisting pathogenic microbes, blood sugar lowering, and resisting fatigue, antioxidation, slow down aging, hemostasis resists myocardial ischemia effects such as antiviral.But Rhizoma Polygonati is not reported as yet about the research of estrogen-like effects aspect.
Three, summary of the invention
At above-mentioned situation, the present invention's purpose just provides the application in a kind of Rhizoma Polygonati water extract climacteric syndrome medicine that the estrogen hyposecretion causes in preparation is treated owing to body, can effectively solve the medication problem that the climacteric syndrome that causes owing to estrogen hyposecretion in the body is treated in preparation.
The technical scheme that the present invention solves is, Rhizoma Polygonati is boiled 2 times with the decocting of its 10 times of weight at every turn, each 2h, merge 2 times decocting liquid, the concentrating under reduced pressure drying obtains Rhizoma Polygonati extractum shape water extract, this Huang water extract is effective to prepare the medicine for the treatment of the climacteric syndrome that causes owing to estrogen hyposecretion in the body, i.e. application in the Rhizoma Polygonati water extract climacteric syndrome medicine that the estrogen hyposecretion causes in preparation is treated owing to body.
Water extract preparation method of the present invention is simple, reliable and stable, and through repeatedly test more than (inferior surplus in the of 30), all obtained identical or akin result, convenient, cost is low, its water extract is effective to prepare the estrogen medicine, has opened up the medicinal new purposes of Rhizoma Polygonati, and clinical meaning is huge.
Four, the specific embodiment
The specific embodiment of the present invention is elaborated with relevant testing data below in conjunction with embodiment.
At first Rhizoma Polygonati (Polygonatum kingianum Coll.et Hemsl.) 100g is used at every turn the water 1000g (being 1000ml) of its 10 times of weight to decoct 2 times, each 2h, merge decocting liquid twice, the concentrating under reduced pressure drying obtains Rhizoma Polygonati extractum shape water extract 65.46g, this water extract is effective to prepare the medicine for the treatment of the climacteric syndrome that causes owing to estrogen hyposecretion in the body, promptly realize the application in the Rhizoma Polygonati water extract climacteric syndrome medicine that the estrogen hyposecretion causes in preparation is treated owing to body, and obtained fully proving that its relevant testing data is as follows through animal experiment:
At first by MCF-7 cell proliferation experiment (E-SCREEN), prove that Rhizoma Polygonati can promote the MCF-7 cell proliferation, illustrate that it has an estrogen-like effects external.
By Mouse Uterus weightening finish experiment, the checking Rhizoma Polygonati can increase the uterus coefficient of sex immature mice, illustrates that it has estrogen-like effects in vivo.
Proved the new purposes of medicine of the present invention in the estrogen medicine by experiment:
One, experiment material and method
1. the preparation of medicine
Rhizoma Polygonati (Polygonatum kingianum Coll.et Hemsl.) 100g boils 2 times with the decocting of 10 times of amounts, each 2h, and decocting liquid concentrating under reduced pressure drying obtains Rhizoma Polygonati water extract 65.46g (extractum shape).
2. laboratory animal and cell strain
Kunming mouse, female, be born 21 days (ablactation just).Body weight 9～12g purchases the Experimental Animal Center in Henan Province.Human breast cancer cell (MCF-7) is provided by Chinese BIO ENGINEERING INST MILITARY.
3. main agents
(Newborn Calf Serum is NCS) available from GibcoInvitrogen company for RPMI1640 culture medium, calf serum; Do not have phenol red RPMI1640 culture medium, 17 beta estradiols (17 β-estrogen, E2), active carbon (Charcoal) is all available from Sigma company; Glucosan T-70 (Dextran-70) is available from Shanghai chemical reagents corporation; Synestrin tablets (Hefei joins pharmacy for a long time).
4. used key instrument
Electronical reading analytical balance (Japanese Shimadzu company); The general surgery apparatus; CO2 gas incubator (Japanese SANYO company); Inverted microscope (Japanese Olympus); KDC-160HR high-speed low temperature refrigerated centrifuger (Keda Innovation Co., Ltd); Microplate reader (BIO-RAD 680).
5. experimental technique
(1) Mouse Uterus weightening finish experiment
Mice is balanced by body weight and principle is at random divided into groups.Administration continues 7 days.Blank group distilled water every day 0.2ml.10g
-1Irritate stomach; Positive controls diethylstilbestrol every day suspension (0.035mgkg
-1D
-1) the filling stomach; Rhizoma Polygonati calculates by 20 times of amount * extraction ratios of clinical application, is made into the suspension of respective concentration, presses 0.02ml/10g every day and irritates stomach filling stomach.Behind the last administration 24h, take off neck and put to death mice, win the uterus immediately and weigh, calculate uterus coefficient (uterus weight in wet base (body weight)
-1100%).Test parallel triplicate.The result compares with the blank group, and calculating the investigation of P value has not statistically significant.
(2) MCF-7 cell proliferation experiment
The MCF-7 cell is chosen the exponential phase cell after not having phenol red 1,640 2 weeks of cultivation, PBS washes twice, behind 0.25% trypsinization, adds serum-free 1640 piping and druming evenly, with 2 * 10
3The concentration in individual/hole is inoculated in 96 orifice plates, and it is 200 μ l that cumulative volume is cultivated in every hole.Cultivate treated cell attachment in 24 hours after, be changed to the pastille culture fluid and continue cultivate.37 ℃, 5%CO
2Cultivate after 3 days, every hole adds MTT solution (5mg/ml) 20 μ l, and 37 ℃ are continued to cultivate 4 hours, the culture fluid that carefully exhausts, and every hole adds 150 μ lDMSO, shakes 5～10 minutes, and crystal is dissolved fully.With the DMSO zeroing, under 490nm, measure each hole absorbance (A) with microplate reader, the calculating average A value and the rate of increase (Proliferation Rate, RP).Test parallel triplicate.
RP=(experimental group A value/blank group A value)-1 * 100%
6. statistical disposition
Experimental data with
Expression, SPSS13.0 carries out one factor analysis of variance (One-Way ANOVA) statistical disposition.
Two, experimental result
1. Rhizoma Polygonati is to the influence of MCF-7 cell proliferation
Rhizoma Polygonati has the short significantly proliferation function (P＜0.01) of the utmost point to MCF-7 cell and blank group ratio when 0.1mg/ml.See Table 1.Illustrate that Rhizoma Polygonati has an estrogen-like effects external.
Table 1 Rhizoma Polygonati is to the influence of MCF-7 cell proliferation
2. Rhizoma Polygonati is to the influence of sex immature Mouse Uterus coefficient
The result shows that the Rhizoma Polygonati group is compared the utmost point with the blank group increase Mouse Uterus coefficient (P＜0.01) significantly.See Table 2.Illustrate that Rhizoma Polygonati has estrogen-like effects in the mice body.
Table 2 Rhizoma Polygonati is to the influence of sex immature Mouse Uterus coefficient
Annotate: compare with the blank group, ★ represents P＜0.05, and ☆ represents P＜0.01; Compare with positive controls, ▲ expression P＜0.05, △ represents P＜0.01.
Three, conclusion
The MCF-7 cell is the male human breast cancer cell strain of estrogen receptor (ER), can be subjected to estrogen or estrogenic activity material to regulate and breed specifically, is the cell strain of the most frequently used detection estrogenic activity.MCF-7 cell estrogen-like proliferation test is very sensitive, can distinguish estrogen agonist and antagonist, thereby is widely used in external a large amount of, rapid screening and evaluation environmental estrogens and phytoestrogen.In the experiment of Rhizoma Polygonati to the MCF-7 impact cell, Rhizoma Polygonati has significantly short proliferation function to the MCF-7 cell when 0.1mg/ml, has verified that Rhizoma Polygonati is external to have an estrogen activity.
Above-mentioned test is carried out repeatedly repeatedly, in two years different time carried out 30 surplus time, all obtained identical or close result.
Uterus weight experiment is the classical way of the detection estrogen activity set up the earliest, when estimating estrogen activity, it has considered the absorption, metabolism of material, combine with plasma protein and many-sided factor such as pharmacokinetics, and directly reflection is subjected to the overall biological effect of reagent thing behind internal metabolism.Therefore, this experiment adopts the sex immature female mice uterus weight in wet base and ratio (uterus coefficient) conduct of body weight to estimate the index of estrogen activity.By above-mentioned experiment, the proof Rhizoma Polygonati can promote the uterine growth of sex immature mice, having estrogen-like effects, can be effective to prepare the medicine for the treatment of the climacteric syndrome that causes owing to estrogen hyposecretion in the body, is that one on the Chinese medicine purposes innovated greatly.
Claims (1)
- A Rhizoma Polygonati water extract the preparation treatment owing to body in application in the climacteric syndrome medicine that causes of estrogen hyposecretion, said water extract is that Rhizoma Polygonati boils 2 times with the decocting of its 10 times of weight at every turn, each 2h, merge 2 times decocting liquid, the concentrating under reduced pressure drying obtains Rhizoma Polygonati extractum shape water extract.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102990563A CN101972400A (en) | 2010-10-08 | 2010-10-08 | Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion |
| CN 201110211158 CN102266485A (en) | 2010-10-08 | 2011-07-26 | Application of rhizoma polygonati aqueous extract in preparation of estrogen drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102990563A CN101972400A (en) | 2010-10-08 | 2010-10-08 | Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101972400A true CN101972400A (en) | 2011-02-16 |
Family
ID=43572332
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102990563A Withdrawn CN101972400A (en) | 2010-10-08 | 2010-10-08 | Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion |
| CN 201110211158 Pending CN102266485A (en) | 2010-10-08 | 2011-07-26 | Application of rhizoma polygonati aqueous extract in preparation of estrogen drugs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110211158 Pending CN102266485A (en) | 2010-10-08 | 2011-07-26 | Application of rhizoma polygonati aqueous extract in preparation of estrogen drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN101972400A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110367537A (en) * | 2019-08-08 | 2019-10-25 | 哈福科技（武汉）集团有限公司 | A kind of functional food and preparation method thereof improving menopausal syndrome |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816376A (en) * | 2013-12-27 | 2014-05-28 | 柳州市工人医院 | Traditional Chinese medicine composite for improving endometrium receptivity, and preparation method of traditional Chinese medicine composite |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005298450A (en) * | 2004-04-15 | 2005-10-27 | Taisho Pharmaceut Co Ltd | Prophylactic or therapeutic agent composition for menopausal syndrome |
| CN1931319A (en) * | 2005-09-16 | 2007-03-21 | 张玲 | Medicine for treating female climacteric syndrome and endocrine disorder and its prepn process |
| CN1742976A (en) * | 2005-09-23 | 2006-03-08 | 北京润德康医药技术有限公司 | Chinese medicine preparation-shugeng and preparing method |
-
2010
- 2010-10-08 CN CN2010102990563A patent/CN101972400A/en not_active Withdrawn
-
2011
- 2011-07-26 CN CN 201110211158 patent/CN102266485A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110367537A (en) * | 2019-08-08 | 2019-10-25 | 哈福科技（武汉）集团有限公司 | A kind of functional food and preparation method thereof improving menopausal syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102266485A (en) | 2011-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106501434B (en) | A kind of HPLC finger print measuring methods of Double Harmonizing Decoction standard soup | |
| CN102973693B (en) | Pharmaceutical composition used for relaxing bowels to lose weight, and preparation method and application thereof | |
| CN102805756B (en) | Application of extract of Chimonanthus Salicifolius. S.Y.H. in preparation of gastric cancer treating medicine | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN102631595B (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN101972400A (en) | Application of sealwort extract to preparing medicament for treating women climacteric metancholia caused by in vivo female hormore hyposecretion | |
| CN110898102B (en) | Cinnamon extract and traditional Chinese medicine compound for preventing and treating cold injury and application thereof | |
| CN101966254A (en) | Application of raw rehmannia aqueous extract in preparing medicines for treating woman climacteric syndrome caused by hyposecretion of in-vivo female hormones | |
| CN103690574A (en) | Poria-containing traditional Chinese medicine combination for enhancing immunity and preparation method of poria-containing traditional Chinese medicine combination | |
| Yang et al. | Study onin vitro anti-tumor activity of Bidens bipinnata L. extract | |
| CN101293015B (en) | Chinese medicinal composition, preparation method and application thereof | |
| CN101168008B (en) | Medicinal composition with tumor inhibition function and preparation method and application thereof | |
| WO2005084689A1 (en) | Radix astragli extract and production method and use thereof | |
| CN102813807A (en) | Traditional Chinese medicine decoction for treating kidney and yin deficiency type diabetes | |
| CN102652774A (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN101732419A (en) | Application and preparation method of extract from fructus polygoni orientalis | |
| CN102861159A (en) | Medicine composition for treating dysmenorrheal as well as preparation method and application thereof | |
| CN113322298A (en) | Biological limit value determination method for Qingjin phlegm-resolving decoction | |
| CN101028311B (en) | Use of selaginella tamariscina | |
| CN114869977B (en) | Application of lung cough in preparation of product for preventing and treating breast cancer | |
| CN105560313B (en) | A kind of compound Jin stork herbal medicine object and preparation method thereof for treating diabetes | |
| CN109223762A (en) | Glabrene is preparing the application in anticancer drug | |
| CN108853337A (en) | A kind of herbal cuisine and preparation method thereof for Cancer related fatigue to be mitigated or eliminated | |
| CN102579673B (en) | Application of fresh rehmannia root aqueous extract in preparation of estrogen medicines | |
| CN103083523B (en) | Traditional Chinese medicine composition for treating chronic prostatitis and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Open date: 20110216 |